Pluri Inc PLUR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Pluri Adds ISO 9001 and ISO 13485 Certifications to Support PluriCDMO Commercial Expansion
Pluri to Host Investor Conference Calls to Discuss Updates and Strategic Developments
Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine
Pluri Chairman and Active Investor Alejandro Weinstein to Acquire EIB Loan, in Strong Vote of Confidence in the Company
Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor
Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment
Trading Information
- Previous Close Price
- $1.24
- Day Range
- $1.05–1.26
- 52-Week Range
- $0.00–4.87
- Bid/Ask
- $1.15 / $1.21
- Shares Outstanding
- 13.52M
- Market Cap
- $15.95M
- Volume/Avg
- 41,255 / 34,769
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 11.85
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 113
Valuation
Metric | PLUR |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 11.85 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | PLUR |
|---|---|
Quick Ratio | 0.25 |
Current Ratio | 0.27 |
Interest Coverage | −26.77 |
Quick Ratio
PLUR
Profitability
Metric | PLUR |
|---|---|
Return on Assets (Normalized) | −69.77% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −83.91% |
Return on Assets
PLUR
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|>jqHfPT | LOCK|ys?M# | $139B | |||
| Moderna Inc MRNA | LOCK|K##r?$Q | LOCK|FSt | $103B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|x<R@#LV | LOCK|@K<! | $94B | |||
| argenx SE ADR ARGX | LOCK|HL?^y&W | LOCK|BYQ | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|BQn>QY | LOCK|g%X | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|gXnj>M@ | LOCK|J$!@> | $30B | |||
| Incyte Corp INCY | LOCK|fh&ds$p | LOCK|nm | $24B | |||
| BioNTech SE ADR BNTX | LOCK|@#P^?^# | LOCK|%pG | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|%>XJ?Nr | LOCK|q#<z | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|?S<GD#^ | LOCK|%ZJ | $15B |
United States